IBD Plexus Publications
09/19/2023
IBD Partners
Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
Crohn's & Colitis 360
Manuscript09/11/2023
SPARC IBD
Utilization of Treat-to-Target Monitoring Colonoscopy after Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
The American Journal of Gastroenterology
Manuscript07/23/2023
SPARC IBD
Interpretable histopathology-based prediction of disease relevant features in Inflammatory Bowel Disease biopsies using weakly-supervised deep learning
Medical Imaging with Deep Learning Conference
Abstract/Poster07/23/2023
IBD Partners
QALYs: The Math Doesn’t Work
Journal of HEOR
Manuscript07/21/2023
SPARC IBD
Assessing Progression of Biologic Therapies Based on Smoking Status in Patients With Crohn’s Disease
Inflammatory Bowel Diseases
Manuscript06/26/2023
SPARC IBD
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
Inflammatory Bowel Disease
Manuscript06/19/2023
SPARC IBD
Uncovering genetic mechanisms of inflammatory bowel disease through DNA-RNA integration analyses of the inflamed colon tissue
European Human Genetics Conference
Abstract/Poster06/16/2023
SPARC IBD
Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough
Clinical Gastroenterology and Hepatology
Manuscript05/29/2023
IBD Partners
Results from the COMPARE Study – How Do Different Medications Impact IBD Patients? Ulcerative Colitis
Crohn's & Colitis 360
Manuscript05/29/2023
SPARC IBD
Comparing Patient Reported Outcomes among Anti-TNF Experienced Patients with Ulcerative Colitis Initiating Vedolizumab versus Tofacitinib
Crohn's & Colitis 360
Manuscript